Hepatitis B Cure Closer After Gene Editing Eliminates Viral Reservoir in Every Target-Dose Patient
Precision BioSciences presented Phase 1 data at AASLD 2026 showing its gene-editing therapy PBGENE-HBV eliminated hepatitis B viral reservoirs in 92% of target-dose patients. The study involved 25 patients, with 11 of 12 achieving undetectable pgRNA, a key biomarker. Precision plans to advance to a global Phase 2 study.
How this was made
The 30-second read
Why it matters
The data could position Precision as a leader in curative HBV therapies, influencing investor sentiment across gene‑editing biotech stocks.
Market read
First‑time demonstration of durable cccDNA clearance may trigger re‑rating of Precision and spur sector‑wide interest in gene‑editing cures.
What to watch
Regulatory pathway for in‑vivo gene editing is uncertain; manufacturing scale‑up and LNP delivery costs not discussed.
Background
Precision BioSciences' ARCUS platform differs from CRISPR, offering a single‑protein nuclease with longer target sequence, potentially reducing off‑target effects.
Ticker impact
Precision BioSciences presented Phase 1 data showing 92% of patients achieved undetectable pgRNA after ARCUS gene editing, a first report of durable cccDNA elimination.
upward pressure as market prices in the breakthrough data
First disclosure of durable viral reservoir clearance; biotech investors react strongly to early‑stage success.
Market effects
May boost confidence in gene‑editing platforms and increase interest in hepatitis B therapeutics.
U.S. biotech sector could see modest gains; Asian HBV drug developers may face heightened competition.
Highlights the potential of ARCUS technology globally, could attract cross‑border partnerships.
Counterpoint
Phase 1 data are early; efficacy in larger, diverse populations remains unproven, risk of overvaluation.
Key entities
- CompanyPrecision BioSciences
Durham‑based biotech developing ARCUS gene‑editing therapies.
- CompanyAcuitas Therapeutics
LNP formulation partner for PBGENE‑HBV.
